Recombinant Human AMHRII Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02758P-100UG
Human AMHRII on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human AMHRII Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02758P-100UG
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human AMHRII Protein is expressed from HEK293 without tag.It contains Pro18-Ser144. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q16671 |
Target Symbol | AMHRII |
Synonyms | MIS type II receptor; MISRII; MRII; AMHR; MISR2; AMHR2; AMH type II receptor; AMHR2; AMHRII; C14 |
Species | Human |
Expression System | HEK293 |
Tag | No Tag |
Expression Range | Pro18-Ser144 |
Mol. Weight | The protein has a predicted MW of 14.3 kDa. Due to glycosylation, the protein migrates to 30-40 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human AMHRII at 1ug/ml (100ul/Well) on the plate. Dose response curve for Anti-AMHRII Antibody, hFc Tag with the EC50 of 15.6ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | The aim of the current study was to explore whether anti-Müllerian hormone receptor II (AMHRII) genetic variants influence the hormonal profile and the ovarian response to standard gonadotropin stimulation of women undergoing medically assisted reproduction. Three hundred in vitro fertilization or intracytoplasmic sperm injection patients constituted the study population, while 300 women with at least one spontaneous pregnancy participated as controls. |